Pantoc (Pantoprazole)

Pantoprazole is a proton pump inhibitor that acts on the acid‑secretion pathway of the stomach. It is indicated for several gastrointestinal disorders:

• Gastro‑oesophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis.
• Erosive esophagitis: accelerates mucosal healing and reduces symptom recurrence.
• Zollinger‑Ellison syndrome: controls gastric acid hypersecretion associated with gastrin‑producing tumours.
• Peptic ulcer disease prevention: lowers ulcer risk when used with NSAIDs or in high‑risk patients.
• Helicobacter pylori eradication regimens: serves as a component of triple‑therapy protocols to improve eradication rates.

• Pantoprazole selectively and irreversibly binds to the H+/K+‑ATPase enzyme (the gastric proton pump) on the secretory surface of parietal cells. By inhibiting this final step of acid production, it markedly reduces both basal and stimulated gastric acidity, allowing ulcer healing and symptom control.

Pantoprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhoea: usually self‑limiting.
• Abdominal pain or discomfort.
• Nausea or vomiting.
• Flatulence: excess gas.
• Constipation: occasional.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis): rash, swelling, breathing difficulty.
• Clostridioides difficile‑associated colitis: persistent diarrhoea.
• Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat.
• Bone fractures: increased risk with long‑term use.
• Liver enzyme elevation: hepatitis‑like picture.
• Acute interstitial nephritis: kidney inflammation.

When prescribing Pantoprazole, clinicians should consider several safety aspects:

• Renal impairment: dose adjustment may be required in severe kidney disease.
• Hepatic impairment: monitor liver function in patients with liver disease.
• Long‑term therapy: assess need for periodic review to avoid bone‑density loss.
• Drug interactions: review concomitant medications that affect gastric pH or CYP enzymes.
• Pregnancy and lactation: use only if clearly needed after risk‑benefit evaluation.
• Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture and direct sunlight.

Pantoprazole can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid)

• Antifungal agents (ketoconazole, itraconazole): reduced absorption due to higher gastric pH.
• HIV protease inhibitors (atazanavir, nelfinavir): markedly decreased plasma levels.
• Clopidogrel: diminished antiplatelet effect, consider alternative therapy.

Moderate Interactions (Monitor Closely)

• Warfarin: potential increase in INR, monitor coagulation.
• Methotrexate: reduced renal clearance, watch for toxicity.
• Digoxin: slight increase in serum concentration, check levels if clinically indicated.